Peñarrubia-María María Teresa, Parker Lucy Anne, Puig-García Marta, Fuente-Moreno Marina, Lumbreras Blanca, Lopez-Pintor Elsa, Domenech Abella Joan, Saez Marc, Dima Alexandra Lelia, Figueiras Guzmán Adolfo, Chilet Rosell Elisa, Serrano-Blanco Antoni, Aznar-Lou Ignacio
EAP Bartomeu Fabrés Anglada, Institut Català de la Salut, IDIAP Jordi Gol, Barcelona, Catalunya, Spain.
Universitat de Barcelona Facultat de Medicina i Ciencies de la Salut, Barcelona, Catalunya, Spain.
Fam Med Community Health. 2025 Jul 31;13(3):e003233. doi: 10.1136/fmch-2024-003233.
Long-term use of benzodiazepines (BZD) triggers health problems. Although Spain leads European use of BZD, the number of long-term users (LTUs) remains unknown.
The aim of the study is to estimate the proportion of primary care (PC) patients who initiate a BDZ prescription that subsequently become LTU and to identify its associated factors.
Retrospective real-world data cohort.
It included the population over 15 years with a new prescription of BZD in PC in Catalonia. Users were considered LTU if they had been dispensed at least three prescriptions within 3 months. Sociodemographic characteristics of patients and prescribers, pathologies, previous BZD use, number and type of visits, and prescription quality standard were considered. We estimated the proportion of LTU among patients with a new prescription, stratified by age and sex, and estimated risk factors by multivariate generalised linear models.
100 638 users with a new BZD prescription were included. 27.1% were LTU at 3 months and 14.5% at 6 months. LTU increases with age and is higher in women. Predictors of LTU are Spanish nationality, living in rural areas, having a mental illness, having used BZD, having virtual visits or not meeting pharmacy-therapeutic quality standards.
The number of patients who develop LTU is high, especially in the elderly. Exploring the causes of this phenomenon could contribute to the development of future interventions.
长期使用苯二氮䓬类药物(BZD)会引发健康问题。尽管西班牙在欧洲BZD的使用量居首,但长期使用者(LTU)的数量仍不明确。
本研究旨在估算开始使用BZD处方后成为LTU的初级保健(PC)患者比例,并确定其相关因素。
回顾性真实世界数据队列研究。
研究纳入了加泰罗尼亚地区15岁以上在PC中新开具BZD处方的人群。如果患者在3个月内至少获得了三张处方,则被视为LTU。研究考虑了患者和开处方者的社会人口学特征、病理情况、既往BZD使用情况、就诊次数和类型以及处方质量标准。我们按年龄和性别对新处方患者中的LTU比例进行了估算,并通过多变量广义线性模型估算了风险因素。
纳入了100638名新开具BZD处方的使用者。3个月时27.1%为LTU,6个月时为14.5%。LTU比例随年龄增长而增加,女性更高。LTU的预测因素包括西班牙国籍、居住在农村地区、患有精神疾病、曾使用过BZD、进行过虚拟就诊或未达到药学治疗质量标准。
发展为LTU的患者数量众多,尤其是老年人。探究这一现象的原因有助于未来干预措施的制定。